Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Oct 16, 2014; 2(10): 565-568
Published online Oct 16, 2014. doi: 10.12998/wjcc.v2.i10.565
Published online Oct 16, 2014. doi: 10.12998/wjcc.v2.i10.565
Chemotherapy induced Takotsubo cardiomyopathy
Sunny Goel, Abhishek Sharma, Abhinav Chandra, Vijay Shetty, Department of Medicine, Maimonides Medical Center, Brooklyn, NY 11219, United States
Aakash Garg, Department of Internal Medicine, James J. Peters VA Medical Center, Mount Sinai School of Medicine, Bronx, NY 10468, United States
Author contributions: All the authors contributed to this work.
Correspondence to: Abhishek Sharma, MD, Department of Medicine, Maimonides Medical Center, 4802 Tenth Avenue, Brooklyn, NY 11219, United States. abhisheksharma4mamc@gmail.com
Telephone: +1-201-8926548
Received: May 24, 2014
Revised: June 23, 2014
Accepted: July 18, 2014
Published online: October 16, 2014
Revised: June 23, 2014
Accepted: July 18, 2014
Published online: October 16, 2014
Abstract
Chemotherapy has been linked with Takotsubo cardiomyopathy. Most of the literature on chemotherapy associated Takotsubo cardiomyopathy is on the drug 5-fluorouracil. In this report, we describe the case of a 55-year-old Asian male who developed Takotsubo cardiomyopathy while receiving dual chemotherapy with cytarabine and daunorubicin for acute myeloid leukemia. To our knowledge, it is the first case of Takotsubo cardiomyopathy associated with daunorubicin and/or cytarabine.
Keywords: Takotsubo cardiomyopathy, Chemotherapy, Cytarabine, Daunorubicin
Core tip: In this case report, we describe first case of Takotsubo cardiomyopathy associated with daunorubicin and/or cytarabine.